A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial Of Selinexor In Maintenance Therapy After Systemic Therapy For Patients With P53 Wild-Type, Advanced Or Recurrent Endometrial Carcinoma
Posted Date: Apr 25, 2024
- Investigator: Amanda Jackson
- Specialties: Cancer, Gynecologic Oncology, Oncology
- Type of Study: Drug
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy.
Criteria:
Null
Keywords:
Endometrial
For More Information:
Jessica Mullins
NULL
cancer@uchealth.gov